AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 73, Issue 2, 2018, Pages 328-340

  Jensen Jarolim, E ^a,b   Bax, H J ^c   Bianchini, R ^a   Crescioli, S ^c   Daniels Wells, T R ^d   Dombrowicz, D ^e   Fiebiger, E ^f   Gould, H J ^g   Irshad, S ^c,h   Janda, J ⁱ   Josephs, D H ^c   Levi Schaffer, F ^j   O'Mahony L ^k   Pellizzari, G ^c   Penichet, M L ^d   Redegeld, F ^l   Roth Walter, F ^a,b   Singer, J ^b   Untersmayr, E ^b   Vangelista, L ^m   Karagiannis, S N ^c,h   more..

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIV LILLE   (France)

^f Boston s Children Hospital   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^k SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^l UTRECHT UNIVERSITY   (Netherlands)

^m NAZARBAYEV UNIVERSITY   (Kazakhstan)

more..

Author keywords

allergooncology; allergy; cancer; oncoimmunology; tolerance

Indexed keywords

ALLERGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FREE LIGHT CHAIN; GAMMA INTERFERON; HEPARIN; HISTAMINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; INTERLEUKIN 8; LIPOCALIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NERVE GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLERGY; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; DENDRITIC CELL; EOSINOPHIL; EPITHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LIGHT CHAIN; LYMPHOID CELL; MACROPHAGE; MALIGNANT NEOPLASM; MAST CELL; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; REGULATORY B LYMPHOCYTE; REGULATORY T LYMPHOCYTE; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; NEOPLASM; PROCEDURES;

DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS;

EID: 85040675651     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.13311     Document Type: Article

References (121)

1. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6:353-360.
2. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170-181.
3. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133:621-631.
4. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903-907.
5. Schatton T, Schutte U, Frank MH. Effects of malignant melanoma initiating cells on T-cell activation. Methods Mol Biol. 2016; [Epub ahead of print].
6. Angelin A, Gil-de-Gomez L, Dahiya S, et al. Foxp3 reprograms T Cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25:1282-1293.
7. Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol. 2011;24:801-809.
8. van de Veen W, Stanic B, Wirz OF, Jansen K, Globinska A, Akdis M. Role of regulatory B cells in immune tolerance to allergens and beyond. J Allergy Clin Immunol. 2016;138:654-665.
9. Gueguen C, Bouley J, Moussu H, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016;137:545-558.
10. James LK, Till SJ. Potential mechanisms for IgG4 inhibition of immediate hypersensitivity reactions. Curr Allergy Asthma Rep. 2016;16:23.
11. Jensen-Jarolim E, Roth-Walter F, Pacios LF, et al. IgG4 drives M2 macrophages to cortisol, Lcn-2 and IL-10 release: implications in maintenance of tolerance and allergen immunotherapy. J Allergy Clin Immunol. 2016;137:Ab403.
12. Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017;72:1156-1173.
13. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005;6:280-286.
14. Chen X, Shao Q, Hao S, et al. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017;8:13703-13715.
15. Robainas M, Otano R, Bueno S, Ait-Oudhia S. Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. Onco Targets Ther. 2017;10:1803-1807.
16. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
17. Enewold L, Sharon E, Harlan LC. Metastatic melanoma: treatment and survival in the US after the introduction of ipilimumab and vemurafenib. Oncol Res Treat. 2017;40:174-183.
18. Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29:136-144.
19. Lonberg N, Korman AJ. Masterful antibodies: checkpoint blockade. Cancer Immunol Res. 2017;5:275-281.
20. Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev. 2017;54:74-86.
21. Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18:599-610.
22. Valecha GK, Vennepureddy A, Ibrahim U, Safa F, Samra B, Atallah JP. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Rev Anticancer Ther. 2017;17:47-59.
23. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233-1247.
24. Jensen-Jarolim E, Achatz G, Turner MC, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008;63:1255-1266.
25. Jensen-Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy. 2017;72:866-887.
26. Jensen-Jarolim E, Turner MC, Karagiannis SN. AllergoOncology: IgE- and IgG4- mediated immune mechanisms linking allergy with cancer and their translational implications. J Allergy Clin Immunol. 2017; pii: S0091-6749(17)30758-3 [Epub ahead of print].
27. Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol. 2014;5:7.
28. Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man. Front Immunol. 2015;6:569.
29. Luo X, Tarbell KV, Yang H, et al. Dendritic cells with TGF-beta1 differentiate naive CD4+ CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci USA. 2007;104:2821-2826.
30. Platzer B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol. 2015;8:516-532.
31. Platzer B, Elpek KG, Cremasco V, et al. IgE/FcepsilonRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep. 2015; pii: S2211-1247(15)00143-6 [Epub ahead of print].
32. Khanduja KL, Kaushik G, Khanduja S, Pathak CM, Laldinpuii J, Behera D. Corticosteroids affect nitric oxide generation, total free radicals production, and nitric oxide synthase activity in monocytes of asthmatic patients. Mol Cell Biochem. 2011;346:31-37.
33. Jiang Z, Zhu L. Update on the role of alternatively activated macrophages in asthma. J Asthma Allergy. 2016;9:101-107.
34. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.
35. Asai A, Nakamura K, Kobayashi M, Herndon DN, Suzuki F. CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. J Leukoc Biol. 2012;92:859-867.
36. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-896.
37. Josephs DH, Bax HJ, Dodev T, et al. Anti-folate receptor-alpha IgE but not IgG recruits macrophages to attack tumors via TNFalpha/MCP-1 signaling. Cancer Res. 2017;77:1127-1141.
38. Karagiannis SN, Josephs DH, Bax HJ, Spicer JF. Therapeutic IgE antibodies: harnessing a macrophage-mediated immune surveillance mechanism against cancer. Cancer Res. 2017;77:2779-2783.
39. Wawrzyniak M, O'Mahony L, Akdis M. Role of regulatory cells in oral tolerance. Allergy Asthma Immunol Res. 2017;9:107-115.
40. Josefowicz SZ, Niec RE, Kim HY, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature. 2012;482:395-399.
41. Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4: pii:E28.
42. Roth-Walter F, Bergmayr C, Meitz S, et al. Janus-faced acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: mouse model for passive respiratory exposure. Sci Rep. 2017;7:45067.
43. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109-118.
44. Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest. 2013;123:1457-1474.
45. Saul L, Ilieva KM, Bax HJ, et al. IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci Rep. 2016;6:29736.
46. Coker HA, Durham SR, Gould HJ. Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol. 2003;171:5602-5610.
47. Chiaruttini G, Mele S, Opzoomer J, et al. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment. Oncoimmunology. 2017;6:e1294296.
48. Braza F, Chesne J, Castagnet S, Magnan A, Brouard S. Regulatory functions of B cells in allergic diseases. Allergy. 2014;69:1454-1463.
49. Linnebacher M, Maletzki C. Tumor-infiltrating B cells: the ignored players in tumor immunology. Oncoimmunology. 2012;1:1186-1188.
50. Olkhanud PB, Damdinsuren B, Bodogai M, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71:3505-3515.
51. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol. 2016;138:1253-1264.
52. Mattner J, Wirtz S. Friend or Foe? The ambiguous role of innate lymphoid cells in cancer development. Trends Immunol. 2017;38:29-38.
53. Mjosberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138:1265-1276.
54. Mortha A, Chudnovskiy A, Hashimoto D, et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science. 2014;343:1249288.
55. Cortez VS, Robinette ML, Colonna M. Innate lymphoid cells: new insights into function and development. Curr Opin Immunol. 2015;32:71-77.
56. Varricchi G, Galdiero MR, Loffredo S, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424.
57. Groot Kormelink T, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des. 2009;15:1868-1878.
58. Gottfried E, Kreutz M, Mackensen A. Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol. 2012;22:335-341.
59. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71:6921-6925.
60. Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 2006;176:2238-2248.
61. Rodrigues CP, Ferreira AC, Pinho MP, de Moraes CJ, Bergami-Santos PC, Barbuto JA. Tolerogenic IDO(+) dendritic cells are induced by PD-1-expressing mast cells. Front Immunol. 2016;7:9.
62. Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2:1-8.
63. Xing Y, Tian Y, Kurosawa T, et al. CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis. Genes Cells. 2016;21:624-638.
64. Gatault S, Delbeke M, Driss V, et al. IL-18 Is involved in eosinophil-mediated tumoricidal activity against a colon carcinoma cell line by upregulating LFA-1 and ICAM-1. J Immunol. 2015;195:2483-2492.
65. Lotfi R, Kaltenmeier C, Lotze MT, Bergmann C. Until death do us part: necrosis and oxidation promote the tumor microenvironment. Transfus Med Hemother. 2016;43:120-132.
66. Wong D, Winter O, Hartig C, et al. Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. PLoS One. 2014;9:e109018.
67. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609-617.
68. Zaynagetdinov R, Sherrill TP, Gleaves LA, et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015;75:1624-1634.
69. Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9:115-121.
70. Lipson EJ, Sharfman WH, Chen S, et al. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med. 2015;13:214.
71. Darcy PK, Neeson P, Yong CS, Kershaw MH. Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol. 2014;27:46-52.
72. Berin MC, Shreffler WG. Mechanisms underlying induction of tolerance to foods. Immunol Allergy Clin North Am. 2016;36:87-102.
73. Shan M, Gentile M, Yeiser JR, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 2013;342:447-453.
74. Untersmayr E, Bises G, Starkl P, et al. The high affinity IgE receptor Fc epsilonRI is expressed by human intestinal epithelial cells. PLoS One. 2010;5:e9023.
75. Bevilacqua C, Montagnac G, Benmerah A, et al. Food allergens are protected from degradation during CD23-mediated transepithelial transport. Int Arch Allergy Immunol. 2004;135:108-116.
76. Jiang L, Shen Y, Guo D, et al. EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance. Nat Commun. 2016;7:13045.
77. Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol. 2016;18:206-215.
78. Friedensohn S, Khan TA, Reddy ST. Advanced methodologies in high-throughput sequencing of immune repertoires. Trends Biotechnol. 2017;35:203-214.
79. Levin M, King JJ, Glanville J, et al. Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy. J Allergy Clin Immunol. 2016;137:1535-1544.
80. Tschumper RC, Asmann YW, Hossain A, et al. Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. Oncotarget. 2012;3:502-513.
81. Schneider C, Smith DF, Cummings RD, et al. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med. 2015;7:269ra261.
82. Santos AF, James LK, Bahnson HT, et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. 2015;135:1249-1256.
83. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011;127:509-516.
84. Bashford-Rogers RJ, Nicolaou KA, Bartram J, et al. Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse. Leukemia. 2016;30:2312-2321.
85. Drayson MT. Using single protein biomarkers to predict health and disease in diverse patient populations: a new role for assessment of immunoglobulin free light chains. Mayo Clin Proc. 2012;87:505-507.
86. Redegeld FA, van der Heijden MW, Kool M, et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med. 2002;8:694-701.
87. Groot Kormelink T, Powe DG, Kuijpers SA, et al. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget. 2014;5:3159-3167.
88. Sironi M, Martinez FO, D'Ambrosio D, et al. Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol. 2006;80:342-349.
89. Barsheshet Y, Wildbaum G, Levy E, et al. CCR8+ FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci USA. 2017;114:6086-6091.
90. Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189:5602-5611.
91. Bronte V, Bria E. Interfering with CCL5/CCR5 at the tumor-stroma interface. Cancer Cell. 2016;29:437-439.
92. Velasco-Velazquez M, Xolalpa W, Pestell RG. The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets. 2014;18:1265-1275.
93. Dilek N, Poirier N, Usal C, Martinet B, Blancho G, Vanhove B. Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol. 2012;188:4209-4216.
94. Umansky V, Blattner C, Gebhardt C, Utikal J. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunol Immunother. 2017;66:1015-1023.
95. Chen X, Churchill MJ, Nagar KK, et al. IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer. Oncotarget. 2015;6:32966-32979.
96. Ribatti D. Mast cells as therapeutic target in cancer. Eur J Pharmacol. 2016;778:152-157.
97. Oldford SA, Marshall JS. Mast cells as targets for immunotherapy of solid tumors. Mol Immunol. 2015;63:113-124.
98. Vila-Leahey A, Oldford SA, Marignani PA, Wang J, Haidl ID, Marshall JS. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016;5:e1151591.
99. Leveson-Gower DB, Sega EI, Kalesnikoff J, et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+ CD25+ regulatory T cells. Blood. 2013;122:3659-3665.
100. Nowak EC, de Vries VC, Wasiuk A, et al. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med. 2012;209:2127-2135.
101. Zaiss DM, van Loosdregt J, Gorlani A, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity. 2013;38:275-284.
102. Lippi G, Meschi T, Nouvenne A, Mattiuzzi C, Borghi L. Neutrophil gelatinase-associated lipocalin in cancer. Adv Clin Chem. 2014;64:179-219.
103. Zhang M, Zhao X, Deng Y, et al. Neutrophil gelatinase associated lipocalin is an independent predictor of poor prognosis in cases of papillary renal cell carcinoma. J Urol. 2015;194:647-652.
104. Makris K, Rizos D, Kafkas N, Haliassos A. Neurophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine. Clin Chem Lab Med. 2012;50:1519-1532.
105. Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell. 2010;141:1006-1017.
106. Li H, Zhang K, Liu LH, et al. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumour Biol. 2014;35:5487-5491.
107. Wen CP, Lee JH, Tai YP, et al. High serum iron is associated with increased cancer risk. Cancer Res. 2014;74:6589-6597.
108. Drury KE, Schaeffer M, Silverberg JI. Association between atopic disease and anemia in US children. JAMA Pediatr. 2016;170:29-34.
109. Roth-Walter F, Gomez-Casado C, Pacios LF, et al. Bet v 1 from birch pollen is a lipocalin-like protein acting as allergen only when devoid of iron by promoting Th2 lymphocytes. J Biol Chem. 2014;289:17416-17421.
110. Jensen-Jarolim E, Pacios LF, Bianchini R, Hofstetter G, Roth-Walter F. Structural similarities of human and mammalian lipocalins, and their function in innate immunity and allergy. Allergy. 2016;71:286-294.
111. Bogh KL, van Bilsen J, Glogowski R, et al. Current challenges facing the assessment of the allergenic capacity of food allergens in animal models. Clin Transl Allergy. 2016;6:21.
112. Jensen-Jarolim E, Pali-Scholl I, Roth-Walter F. Outstanding animal studies in allergy I. From asthma to food allergy and anaphylaxis. Curr Opin Allergy Clin Immunol. 2017;17:169-179.
113. Bellinghausen I, Saloga J. Analysis of allergic immune responses in humanized mice. Cell Immunol. 2016;308:7-12.
114. Smit J, Noti M, O'Mahony L. The use of animal models to discover immunological mechanisms underpinning sensitization to food allergens. Drud Discov Today: Dis Mod. 2015;17–18:63-69.
115. Sanmamed MF, Chester C, Melero I, Kohrt H. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol. 2016;27:1190-1198.
116. Daniels TR, Martinez-Maza O, Penichet ML. Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother. 2012;61:1535-1546.
117. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther. 2008;8:609-632.
118. Walsh NC, Kenney LL, Jangalwe S, et al. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017;12:187-215.
119. Jensen-Jarolim E, Einhorn L, Herrmann I, Thalhammer JG, Panakova L. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy. 2015;5:15.
120. Park JS, Withers SS, Modiano JF, et al. Canine cancer immunotherapy studies: linking mouse and human. J Immunother Cancer. 2016;4:97.
121. Brennan FR, Kiessling A. Translational immunotoxicology of immunomodulatory monoclonal antibodies. Drug Discov Today Technol. 2016;21–22:85-93.